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Key Messages 34 
 Central nervous system involvement  remains an important complication of 35 
syphilis 36 
 CSF Serological assays remain the standard diagnostic test for neurosyphilis 37 
 CSF PCR has poor sensitivity compared to CSF serology and is not the 38 
diagnostic test of choice for neurosyphilis  39 
Abstract: 40 
Introduction:  41 
Syphilis continues to be a major public health problem and the recent resurgence 42 
in syphilis in high-income settings has seen an accompanying increase in cases of 43 
neurosyphilis. Whilst the introduction of PCR has had a significant impact on the 44 
diagnosis of early syphilis, CSF serological assays remain the most commonly 45 
used tests to diagnosis neurosyphilis. We reviewed data on the performance of 46 
CSF-PCR for the diagnosis of neurosyphilis. 47 
Methods: 48 
We searched Pubmed, Medline, EMBASE and the grey literature for references on 49 
PCR in neurosyphilis. We calculated the sensitivity and specificity of PCR 50 
compared to reference testing for the diagnosis of neurosyphilis 51 
Results: 52 
We identified 66 articles of which seven met the study inclusion criteria. The 53 
sensitivity of PCR for definite neurosyphilis varied between 40-70% and 54 
specificity between 60-100% across the studies. The most commonly used PCR 55 
assay targeted Tp47 which had an overall sensitivity of 68% and a specificity of 56 
91.9%. 57 
Discussion: 58 
The sensitivity of PCR was low compared to CSF-serological assays but the 59 
challenges of evaluating a diagnostic test in the absence of a clear gold standard 60 
make definitive interpretation challenging. Most studies were small and not 61 
adequately powered highlighting the need for multi-centre, multi-country trials 62 
to provide adequate statistical power in evaluations of new tests the diagnosis of 63 
neurosyphilis. 64 
Background 65 
Syphilis, caused by Treponema pallidum, remains a major public health problem 66 
worldwide [1]. Infection with syphilis involves progression through a number of 67 
clinical stages. Following an incubation period of approximately 21 days the 68 
primary syphilitic chancre appears. If untreated the disease progresses to 69 
secondary syphilis with dissemination of spirochetes and a generalised illness 70 
often accompanied by a characteristic rash. If the disease is untreated then the 71 
patient enters the latent phase of infection. During this stage the patient is 72 
asymptomatic but has serological evidence of infection. In historical studies in 73 
which patients with latent disease were untreated approximately one third of 74 
patients would progress on to tertiary syphilis[1,2].  75 
 76 
Involvement of the central nervous system (CNS), in the form of neurosyphilis, is 77 
one of the major manifestations of syphilis causing significant debilitation to the 78 
patient. Typically neurosyphilis is described as a late manifestation of infection 79 
occurring during the tertiary stage of infection. Data from both animal models 80 
and human infection clearly demonstrate that invasion of the CNS and 81 
neurological manifestations can occur in both early and late syphilis[3] including 82 
in patients without a clear history of primary syphilis, although the true 83 
incidence of symptomatic neurological disease in early syphilis is not known. For 84 
example, when  lumbar punctures of patients with early syphilis are performed, 85 
evidence of T.pallidum in the Cerebrospinal fluid (CSF) may be identified, even in 86 
those without apparent CNS disease [4] and reports of syphilis with ocular and 87 
cranial nerve involvement have been common during the recent syphilis 88 
epidemics in many countries. In many patients early CNS involvement appears to 89 
resolve without specific CNS targeted therapy[5] but a proportion of patients will 90 
experience clinical CNS disease either during early infection or as a 91 
manifestation of tertiary syphilis.  92 
 93 
Clinically the spectrum of neurosyphilis covers a broad range of presentations. 94 
Five forms are well described: i) asymptomatic neuroinvasion, characterised by 95 
evidence of CNS invasion but no clinical disease; ii) an aseptic meningitis ; iii) 96 
meningovascular disease, characterised by a stroke-like syndrome; iv) tabes 97 
dorsalis, characterised by demyelination of the posterior tracts of the spinal 98 
columns; v) general paresis, characterised by a progressive dementing illness [1].  99 
 100 
Evaluation of the CSF is central to the diagnosis of neurosyphilis although no 101 
universal consensus diagnostic criteria exist. Frequent non-specific 102 
abnormalities found in individuals with neurosyphilis include pleocytosis and 103 
raised protein concentration. Interpretation of these abnormalities is more 104 
difficult in individuals with HIV co-infection, particularly those who are 105 
immunocompromised and/or not on antiretroviral therapy as they may have 106 
CSF pleocytosis as a consequence of other CNS infections or untreated HIV [6,7].  107 
 108 
Serological tests performed on CSF have been the mainstay of diagnostics for 109 
neurosyphilis. The gold standard assay for specificity is normally considered to 110 
be the Venereal Disease Research Laboratory (VDRL) assay but this is known to 111 
have limited sensitivity [8,9]. Whilst the Rapid Plasma Reagin (RPR) assay is 112 
commonly used when testing CSF samples it has reduced sensitivity compared 113 
the VDRL[10].  A variety of other CSF serological assays have been evaluated 114 
including the Fluorescent Treponemal Antibody-adsorption (FTA-ABS)[11] and 115 
Treponema pallidum particle agglutination assays[12]. Whilst these treponemal 116 
specific assays are considered to be more sensitive they are less specific than the 117 
VDRL assay. Some studies have suggested the specificity of the TPPA can be 118 
increased by using a higher titre cut-off albeit at the cost of some sensitivity[13]. 119 
 120 
Polymerase chain reaction (PCR) assays have emerged as valuable diagnostic 121 
tools for early syphilis when applied to genital or other mucocutaneous lesions 122 
[14,15]. Most assays target highly conserved targets including polA and tp47 and 123 
demonstrate good sensitivity and specificity. PCR can also detect circulating 124 
treponemes in the blood of a subset of patients with early infectious and early 125 
latent syphilis[16,17] although the value of PCR in these settings remains less 126 
clear. Given the overall high level of performance it is perhaps unsurprising that 127 
there has been interest in the use of PCR as a possible diagnostic test for 128 
neurosyphilis [7]. Although a number of studies have evaluated PCR assays for 129 
the diagnosis of neurosyphilis its performance compared to alternative 130 
diagnostic assays is not well established. The aim of this study was to review 131 
available data on the performance of PCR for the diagnosis of neurosyphilis in 132 
comparison to reference assays.  133 
  134 
Methods 135 
 136 
Search strategy and selection criteria  137 
We searched Pubmed, Medline, EMBASE and the grey literature for references on 138 
PCR in neurosyphilis. We searched reference lists of selected papers to identify 139 
additional manuscripts. We searched for (“CSF” OR “Cerebrospinal Fluid”) AND 140 
“syphilis” OR “neurosyphilis”) AND (“PCR” OR “Polymerase Chain Reaction” OR 141 
“NAAT” OR “Nucleic Acid Amplification Test”). We limited the search to studies 142 
published between 1st January 1960 and 15th June 2017 (the date the search was 143 
conducted).  144 
 145 
Inclusion end Exclusion Criteria 146 
We included papers that reported the sensitivity and specificity of a PCR assay 147 
against a reference standard in patients with either definite or probable 148 
neurosyphilis. We did not restrict inclusion of data based on the specific PCR 149 
assay or target utilised. No language restrictions were placed on papers included 150 
in the review.  We excluded papers that did not report sensitivity and specificity 151 
of the assay or which did not provide the raw data from which this could be 152 
calculated. We also excluded studies reporting data already described in a 153 
different paper and review papers. 154 
  155 
Data Extraction: 156 
The titles and abstracts of all papers were reviewed by at least two authors (MM, 157 
DL, CK). The full text was obtained for any potentially relevant articles. Full-text 158 
articles were reviewed to determine whether they met the inclusion criteria and 159 
where this was uncertain disagreements were resolved by discussion amongst at 160 
least two authors. Data were initially extracted by the first author and double-161 
checked by the co-authors. For each paper that met the inclusion criteria we 162 
extracted the diagnostic criteria used for neurosyphilis, reference diagnostic test, 163 
the comparator PCR assays evaluated, and the performance of the PCR assay 164 
compared to the reference test.   165 
 166 
Statistical Analysis: 167 
We report the sensitivity and specificity of CSF PCR compared to reference CSF 168 
tests. Where available we stratify results for performance in cases of definite and 169 
suspected neurosyphilis. Due to limited data we pooled data only from studies 170 
assessing a tp47 based PCR assay.  All analysis was performed in R 3.4.2 (The R 171 
Foundation for Statistical Computing). The review was performed in line with 172 
the Preferred Reporting Items for Systematic Review and Meta Analyses 173 
(PRISMA) guidelines[18]. 174 
 175 
  176 
Results 177 
 178 
Our search identified 66 articles of which seven met the inclusion criteria for the 179 
study (Figure 1). These studies enrolled a combined total of 109 patients 180 
classified as having definite neurosyphilis, 13 classified as having probable 181 
neurosyphilis (from only two studies) and 317 classified as not having 182 
neurosyphilis (Table 1)[5,19–24]. 183 
 184 
Five studies reported results for the performance of a Tp47 PCR alone and a 185 
single study reported the combined results of a panel of PCR assays including 186 
TP47, polA and bmp. Two studies reported performance of a polA based PCR, 187 
one of which also independently reported results for a Tp47 assay and one of 188 
which was the evaluation of a panel of Tp47, polA and bmp. A single study 189 
evaluated PCR targeting TMPA (Table 1). The criteria for definite neurosyphilis 190 
varied between studies but the majority (n = 6) required a CSF VDRL to be 191 
positive to make a diagnosis of neurosyphilis, either alone or in combination 192 
with a CSF Treponemal assay. A single study did not use serological assays to 193 
diagnose definite neurosyphilis but instead used a combination of CSF 194 
pleocytosis and raised protein. 195 
 196 
Excluding two small studies the reported sensitivity of the PCR assays for 197 
definite neurosyphilis varied between 40-70% and specificity varied between 198 
60-100% (Table 1). The five studies which reported results for a Tp47 assay 199 
included a total of 88 patients who met the study specific criteria for 200 
neurosyphilis (predominantly CSF VDRL positivity) of which 60 (68%) were 201 
positive using a Tp47 PCR. A total of 210 patients without neurosyphilis were 202 
included and the PCR was negative in 193 of these individuals (91.9%). 203 
Excluding the study which defined neurosyphilis only on the basis of CSF 204 
pleocytosis and raised protein did not alter this finding.  205 
 206 
  207 
Discussion 208 
In this study we have demonstrated the limitations of CSF PCR as a diagnostic for 209 
neurosyphilis whilst also highlighting the limited data currently available to fully 210 
evaluate these assays. The limited performance of PCR for the diagnosis of 211 
neurosyphilis is in marked contrast to the use of PCR for the diagnosis of other 212 
stages of syphilis. PCR has emerged as a key diagnostic tool for early 213 
syphilis[14,25] with a reported sensitivity and specificity above 95% in most 214 
studies. In early syphilis PCR is also able to provide a microbiological diagnosis 215 
before seroconversion occurs, reducing the chance of false negative 216 
investigations in patients presenting with a chancre. In many high income 217 
settings, such as the UK, PCR has become the diagnostic test of choice for primary 218 
syphilis and has increasingly replaced dark-field microscopy. By contrast the 219 
data from this review demonstrates that PCR has lower sensitivity than CSF 220 
VDRL assays for the diagnosis of neurosyphilis. Interpretation of the specificity 221 
of PCR is challenging given the use of VDRL, a test known to have limited 222 
sensitivity, as the reference standard. In some circumstances false-positive PCR 223 
results may actually represent true-positive for the diagnosis of neurosyphilis 224 
which are missed by the current CSF serological assays. 225 
 226 
The evaluation of diagnostic tests for neurosyphilis remains extremely 227 
challenging. There is no accepted gold-standard diagnostic test against which 228 
new candidate tests can be compared. This is evident from the studies included 229 
in this current review which utilised a range of different reference standards 230 
when evaluating the performance of PCR. Whilst CSF VDRL is considered highly 231 
specific the sensitivity is believed to be as low as 40% for detecting 232 
neurosyphilis. A result of this is that evaluations of CSF PCR against CSF VDRL 233 
are likely to result in in an under-estimation of PCR specificity due to true 234 
positives being incorrectly classified. Conversely a previous systematic review 235 
has demonstrated a high sensitivity of CSF treponemal antibody testing[13] but 236 
lower specificity. Comparisons of CSF PCR against CSF Treponemal antibodies 237 
are therefore likely to under-estimate sensitivity due to true-negatives being 238 
incorrectly classified. Indeed even the stated sensitivity or specificity of common 239 
reference standards such as CSF-VDRL or CSF-TPPA are heavily dependent on 240 
the patients included and the criteria used to define neurosyphilis. 241 
As well as analytical challenges in the selection of an appropriate gold-standard, 242 
our review highlights further issues in assessing the role of PCR in the diagnosis 243 
of neurosyphilis. There was no consistent definition of definite or probable 244 
neurosyphilis, variation in the amplification target and relatively small sample 245 
sizes. These between study variations make it difficult to draw definitive 246 
conclusions on the performance of PCR for the diagnosis of neurosyphilis and 247 
highlight the significant challenges in evaluating diagnostic assays for this 248 
condition. Of particular importance, the total number of samples included in each 249 
of the reviewed studies was small and compared to guidelines on the 250 
appropriate sample size for the evaluation of diagnostic tests all the included 251 
samples would be considered underpowered[26].  252 
 253 
Neurosyphilis remains a challenging condition to diagnose. In patients with 254 
positive syphilis serology in blood and evidence of neurological symptoms the 255 
absence of a reliable test means that neurosyphilis treatment is often started 256 
without confirmation of the diagnosis from CSF testing. In patients without 257 
neurological symptoms however, especially those who are HIV positive, there 258 
are concerns surrounding the risk of asymptomatic neurosyphilis with rates as 259 
high as 22% reported[27]. In these patients, neurosyphilis is associated with 260 
increased CNS inflammation but does not appear to explain cognitive 261 
impairment[28]. Given ongoing uncertainties about the significance of 262 
asymptomatic neurosyphilis, there remains debate about the need for CSF 263 
analysis to assess for neurosyphilis in all asymptomatic HIV positive patients. A 264 
recent UK study found that among patients who have received treatment for 265 
early syphilis with benzathine penicillin G, the rates of asymptomatic 266 
neurosyphilis after treatment are low [29].  In view of this the optimal timing 267 
and use of lumbar puncture in the management of syphilis remains 268 
uncertain[30].  269 
 270 
An alternative to lumbar punctures is to prescribe a neuropenetrative antibiotic 271 
regimen to all patients at risk of neurosyphilis without obtaining a confirmatory 272 
diagnosis. The only randomised control trial of using a boosted neuropenetrative 273 
regimen did not find an improved cure rate compared to standard therapy, 274 
although the trial was not powered to specifically address this question in HIV 275 
co-infected individuals[31]. One centre in the UK adopts this approach and has 276 
shown good adherence and serological response to extended treatment[32] but 277 
definitive data remain lacking. A randomised control trial is currently evaluating 278 
the benefit of routine lumbar puncture in those patients for whom it is still not 279 
clear how to proceed.  280 
 281 
Whilst the development of a superior diagnostic test cannot directly answer all 282 
these areas of uncertainty it would certainly aid in clinical decision making, 283 
especially in HIV positive patients. However our data suggest PCR is not that test 284 
and do not support the routine use of CSF-PCR as a diagnostic test for 285 
neurosyphilis. A number of new assays are being evaluated including the B-Cell 286 
chemoattractant CXCL-13 which shows promise[33]. Given the current absence 287 
of a gold-standard assay and the challenges in evaluating assays for the diagnosis 288 
of neurosyphilis, consideration should be given to multi-centre, multi-country 289 
trials to provide adequate power to fully evaluate new tests which may have 290 
superior performance for the diagnosis of neurosyphilis.  291 
 292 
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Figure 1: Flowchart of studies reviewed for inclusion  412 
 413 
 414 
 415 
 416 
 417 
Table 1: Characteristics of Included Studies 
STUDY  
Criteria definite 
neurosyphilis 
Criteria 
probable 
neurosyphilis 
Cases definite 
Neurosyphilis 
Cases 
probable 
Neurosyphilis 
Cases without 
Neurosyphilis 
PCR 
Target 
Sensitivity 
Definite 
Neurosyphilis 
Specificity 
Definite 
Neurosyphilis 
Sensitivity 
Probable 
Neurosyphilis 
Specificity 
Probable 
Neurosyphilis 
Castro et al 
  
CSF TPHA/FTA-ABS 
& WCC>10 OR CSF 
VDRL/RPR 
N/A 33 N/A 91 
tp47 75.80% 86.80%     
polA 69.70% 92.30%     
Dumareq et 
al 
CSF VDRL 
CSF WBC 
count of >20 
cells/ml with a 
nonreactive 
CSF VDRL 
19 11 92 
tp47 & 
polA & 
bmp* 
40% 61% 89% 67% 
Molepo et al 
CSF VDRL & FTA-
ABS 
N/A 35 N/A 15 tp47 65% 66%     
García et al VDRL OR MH-TPA N/A 8 N/A 25 tp47 50% 100%     
Moskophidis 
et al 
CSF Pleocytosis 
& Raised CSF-
Protein & Raided 
CSF-IgG 
N/A 10 N/A 0 tp47 60%       
Marra et al CSF VDRL N/A 2 N/A 79 tp47 100% 100%     
